Therapeutic results of vascular thrombosis and its effective factors in patients after receiving AstraZeneca vaccine in Tabriz

Abstract

Recommended treatments include medication and emergency surgery. However, these treatments have not been able to save the lives of all those involved and the question "which patients with vascular thrombosis survive" still remains. Finding a causal relationship in rare complications is very difficult and never easy, and finding these relationships in very large groups can be found by analyzing the results accurately; Therefore, the aim of this study was to evaluate the treatment outcomes of vascular thrombosis in patients after receiving AstraZeneca vaccine in East Azerbaijan so that we can achieve the relevant results in the treatment outcomes of these patients. Materials and Methods: This is a retrospective study that examined the clinical records of 125 patients with a diagnosis of vascular thrombosis due to vaccination (AstraZeneca) referred to Imam Reza (AS) and Sina hospitals in Tabriz during the first six months of 2021. Done; The results of treatment of these patients and its relationship with demographic characteristics and disease information will be evaluated. Results: The prevalence of vascular thrombosis following vaccination with AstraZeneca vaccine in the present study was 0.2%; The results indicated that the platelet level was significantly lower in deceased patients; The most common type of vascular thrombosis was arterial thrombosis in the upper limbs and deep vein thrombosis in the lower limbs; The first treatment method for patients was anticoagulant therapy in the first stage; After that, 101 patients underwent surgery. The results of the treatment indicated that 36 of the study participants did not respond to any treatment and died. Also, PT and PTT and didimer levels were significantly higher in the group of patients who died than in the group of patients who did not die.